NRF2-HIF2α Signaling Attenuates Endothelial Cell Senescence and Maintains Intercellular Junctions in Diabetes.


Journal

International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568

Informations de publication

Date de publication:
2024
Historique:
received: 28 03 2024
accepted: 15 07 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: epublish

Résumé

In the context of diabetes, endothelial cells frequently exhibit compromised intercellular junctions and accelerated cellular senescence simultaneously. The precise mechanisms underlying these issues and the identification of effective treatments remain largely undefined. Our findings reveal that human umbilical vein endothelial cells (HUVECs) can counteract senescence and uphold the integrity of intercellular junctions under mildly to moderately elevated glucose levels (10 mM and 15 mM) via two primary mechanisms: i) The acetylation of NRF2 at lysine residues K56, K68, and K52 prevents its ubiquitination, enhancing the transcription of antioxidant genes GST, SOD1, and GPX1. This activity diminishes cytoplasmic oxidative stress, thereby mitigating endothelial cell senescence. ii) The interaction between the Neh2 domain of NRF2 and the PAS-B domain of HIF-2α within the nucleus curtails the attachment of HIF-2α to the NOX4/p22phox promoter. This action lessens oxidative stress near the cell membrane, maintaining intercellular junctions by safeguarding the disulfide bonds in occludin and E-cadherin from disruption. However, these protective strategies prove insufficient under severe hyperglycemic conditions (25 mM). Further investigation has identified Oltipraz, an activator of NRF2, as also promoting the degradation of HIF-2α. Through its simultaneous modulation of NRF2 and HIF-2α, Oltipraz significantly reduces cellular senescence and prevents the deterioration of intercellular junctions in HUVECs subjected to high glucose concentrations (25 mM). Our research positions Oltipraz as a promising therapeutic candidate for mitigating diabetes-induced vascular endothelial damage, potentially offering benefits against diabetes-related atherosclerosis and valvular calcification.

Identifiants

pubmed: 39113713
doi: 10.7150/ijbs.96719
pii: ijbsv20p4055
pmc: PMC11302875
doi:

Substances chimiques

NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0
endothelial PAS domain-containing protein 1 1B37H0967P
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4055-4073

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Auteurs

Jian Shen (J)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Yifan Lai (Y)

Wenzhou Municipal Key Cardiovascular Research Laboratory, Department of Cardiology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China.

Yaner Lu (Y)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Yabin Liu (Y)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Jinlong Zhang (J)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Yan Wu (Y)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Yunan Pan (Y)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Haibo Chen (H)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Qiyue Gao (Q)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Qucheng Wei (Q)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Yuwen Chen (Y)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Jian Ye (J)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Yinuo Lin (Y)

Wenzhou Municipal Key Cardiovascular Research Laboratory, Department of Cardiology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China.

Bingchen Liu (B)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Jun Jiang (J)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Jinliang Nan (J)

Department of Cardiology of The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
State Key Laboratory of Transvascular Implantation Devices, Hangzhou 310009, China.
Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou 310009, China.
Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH